Abstract
Our total therapy programme for AML comprises chemotherapy followed by BMT in CR1. From 4/90 to 12/94, 54 pts (13–53 y, med 33.5) received BF12 induction: high-dose ARA-C and VP-16 with idarubicin or mitoxantrone followed by two consolidation cycles. 42 pts attained CR (78%). 32 underwent BMT in CR1; one is awaiting BMT. Of the nine not transplanted in CR1 (early relapse, n = 7; refusal, n = 1; death in CR, n =1), one was transplanted in rell and five in CR2. Subgroup No Cant. CR Relapse Toxic deaths Total deaths Total alive Whole group 54 25 29 (54%) Overall CR 42 23 12 7 13 29 (69%) ABMT in CR1 19 14 3 2 5 14 (71%) Allo in CRl 12 7 1 4 5 7 (58%) Twin in CRl 1 1 − − − 1 No BMT in CR1 10 1 8 1 3 7 (70%) With 54% survival at 3–59 months (median 31) after diagnosis, we believe that this total therapy programme represents state-of-the-art management of AML.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
